The director's cluster of open-market buys totaling ~$950K at ~$9.14-$9.36 per share signals insider conviction near current levels. Monitor for additional insider buying or upcoming catalysts (e.g., pipeline data, regulatory updates) that could validate this signal. The stock's 89% analyst bullish consensus and recent institutional accumulation (7 adds, 6 doubled) provide a supportive backdrop.
RGNX drugs
RGNX drug pipeline →- ▲ surabgene lomparvovec 7/10 Phase 3
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned)
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026)
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 28 $9.66entry
- T+1 · 3mo ago −1.66%α −1.36% · $9.50
- T+5 · 2mo ago −7.45%α −7.56% · $8.94
- T+20 · 7w ago −22.67%α −22.93% · $7.47
- T+55 · todayOpen
- T+60 · in 6d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Gregory Ciongoli made a $450K open-market purchase of RGNX shares at $9.14 on August 26, adding to a $500K purchase the prior day, bringing his total cluster buys to ~$950K. This is a standalone conviction buy by a director, representing ~0.15% of the $619M market cap, which is a modest but notable signal. The purchase follows a non-cash grant of 69,609 shares on August 25, suggesting the director is increasing his economic exposure beyond compensation.
Key Financial Metrics
Key Facts
- Director Gregory Ciongoli purchased 49,196 shares at $9.14 for $450K on August 26, 2026.
- This follows a $500K purchase on August 25 and a non-cash grant of 69,609 shares on the same date.
- Total insider buying in the last 30 days is $949K, all by this director.
- The purchase represents ~0.15% of RGNX's $619M market cap, a modest but material signal.
Financial Impact
$450K open-market purchase by a director, representing ~0.15% of market cap.
Risk Factors
- Single insider (director, not C-suite) limits signal strength; C-suite participation would be more compelling.
- Biotech sector risk: pipeline setbacks or regulatory delays could reverse any near-term gains.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0002023732-26-000008 |
Track record
15 reports on RGNX
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Viewing Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers